Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Anthrax Vaccine Market Expected To Grow In Terms Of Size?

Recent years have seen a constant expansion in the size of the anthrax vaccine market. It’s projected that this market will increase from $11.27 billion in 2024 to $11.77 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.4%. The factors driving growth during the historic period include apprehensions regarding biological warfare, the military’s demand, occurrences of anthrax outbreaks, readiness towards public health, and initiatives in biodefense.

The market size for the anthrax vaccine is anticipated to have continuous expansion in the upcoming years. By 2029, it is projected to achieve a value of “$14 billion with a compounded annual growth rate (CAGR) of 4.4%. This market growth during the forecast span is predicted due to factors such as global security concerns, emergent hazards, governmental buying initiatives, and readiness for pandemics. Furthermore, the forecast period shows significant trends including technology improvements, increased availability in developing nations, concentration on the upcoming generation of vaccines, heightened governmental hoarding, and joint research initiatives.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Anthrax Vaccine Market?

The increase in infectious diseases is projected to boost the expansion of the anthrax vaccine market. Such diseases often stem from harmful microorganisms, including bacteria, fungi, viruses, and parasites, which can transfer directly or indirectly between people. The resulting symptoms could range from mild to severe or even lethal, primarily based on the specific pathogen and the individual’s immune response. The global demographic shifts, urban development, environmental and land use modifications, along with changes in human behavior, are attributing factors to the surge in infectious diseases. The anthrax vaccine, prominently used for anthrax prevention, is also being investigated for broader use against other infectious diseases, considering its immunogenic traits and adaptability. The Council on Foreign Relations, a U.S based non-profit organization, reported in February 2023 that up to 75% of new or emerging infectious diseases (EIDs) and 60% of identified infectious diseases stem from zoonotic origins. Moreover, globally, zoonoses are responsible for 2.7 million human deaths and 2.5 billion instances of human ailments annually. Consequently, the escalation in disease prevalence is propelling the growth of the anthrax vaccine market.

How Is The Global Anthrax Vaccine Market Broken Down By Segment?

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

Which Trends Are Likely To Redefine Growth Paths In The Anthrax Vaccine Market?

Leading firms in the anthrax vaccine market are concentrating their efforts on creating new products and obtaining approval from the FDA for their vaccines, thus ensuring their safety, efficacy, and accessibility to those who might be exposed to anthrax. Receiving FDA approval guarantees that the vaccine has been subjected to stringent clinical trials and deemed fit for public use, hence safeguarding individuals from possible adverse reactions. For example, Emergent BioSolutions Inc., a biopharmaceutical company from the US, got the green light for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly AV7909, from the U.S. Food and Drug Administration (FDA) in July 2023. The endorsement was based on data from a Phase 2 trial assessing Cyfendus’s lack of interference with antibacterial drugs and Phase 3 clinical research comparing the immunogenicity and safety of the vaccine to BioThrax, the previous anthrax vaccine. Moreover, it’s crucial to develop safer and more effective adjuvants to tackle issues related to reactogenicity and increase the overall efficiency of anthrax vaccines.

Who Are The Primary Market Leaders In The Anthrax Vaccine Market?

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Anthrax Vaccine Market?

North America was the largest region in the anthrax vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model